Reports
Global Bladder Cancer Treatment Market Size, Share, Forecast: By Type: Invasive Bladder Cancer, Transitional Bladder Cancer, Squamous Cell Bladder Cancer, Others; By Diagnosis Method: Cystoscopy, Biopsy, Urine Cytology, Imaging Tests; By Treatment Method; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Bladder Cancer Treatment Market Outlook
The bladder cancer treatment market size was close to USD 4.03 billion in 2022, driven by the rising number of bladder cancer cases. The bladder cancer treatment market is likely to grow at a CAGR of 9.31% during the forecast period of 2023-2031 to reach a value of USD 8.98 billion by 2031, driven by the rise in unhealthy lifestyles.
Bladder Cancer Insights
Bladder cancer develops in the tissues of the urinary tract and is known as urological cancer. Cell division occurs uncontrollably in the epithelium and can spread into the bladder's muscular wall.
There is still no clear understanding of what causes bladder cancer. Depending on the type of cancerous cells, bladder cancer can be divided into three categories. The following types are:
Transitional Cell Carcinoma: This type of cancer is also called urothelial carcinoma. The disease occurs in bladder lining cells called urothelial cells. Among all bladder cancer types, this is the most common one.
Squamous Cell Carcinoma: A prolonged infection or stimulation leads to the development of this type of cancer in the bladder.
Adenocarcinoma: Bladder cancer occurs in glands located in the bladder lining. There are only a few cases of this type of bladder cancer.
There are several ways in which non-muscle invasive bladder cancer can be detected, including blood tests, urine cytology, cystoscopy, and computerised tomography.
Chemotherapy, immunotherapy, or surgery are the preferred treatment methods for bladder cancer.
On the other hand, prolonged exposure to radiation, tobacco consumption, chronic bladder infections, and smoking are among the risk factors. Any age group is susceptible to this condition. The condition is more common in older adults. Additionally, smoking is the leading cause of bladder cancer in the world.
According to the market research report, the bladder cancer treatment market can be categorised into the following segments:
Market Breakup by Type
- Invasive Bladder Cancer
- Non-Muscle-Invasive Bladder Cancer
- Muscle-Invasive Bladder Cancer
- Transitional Bladder Cancer
- Squamous Cell Bladder Cancer
- Others
Market Breakup by Diagnosis Method
- Cystoscopy
- Biopsy
- Urine Cytology
- Imaging Tests
Market Breakup by Treatment Method
- Surgery
- Intravesical Chemotherapy
- Systemic Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Market Scenario
The bladder cancer treatment market growth is expected to be influenced by unhealthy lifestyles, such as bladder infections, genetic abnormalities, smoking, and chemical exposure. The bladder cancer treatment market is further expected to grow due to improvements in cancer treatment methods.
The market growth is predicted to be driven by an aging population as well. Increased treatment costs will further limit the growth of the market over the long term. Moreover, emerging markets offer opportunities for market growth. The bladder cancer therapy market, however, may be further hampered by post-treatment side effects.
North America Dominates the Global Bladder Cancer Treatment Market
The market in North America is largely driven by technological advances in medicine, especially cancer treatment. Moreover, bladder cancer treatment will benefit from increased healthcare spending in this region.
Research and development are expected to drive the bladder cancer treatment market growth in Asia-Pacific.
The availability of generic drugs and government awareness programs are also expected to generate significant growth in this region over the next few years.
Therapeutic Landscape
Currently, researchers are testing immune checkpoint inhibitors for bladder cancer in the early stages and in combination with other treatments. The research includes:
- A drug called nivolumab (Opdivo) has been approved by the United States Food and Drug Administration in 2021, as an additional (adjuvant) treatment for patients with urothelial cancer who are at high risk of recurrence after surgery. It was the first FDA approval for this type of adjuvant treatment.
- Avelumab (Bavencio), an immune checkpoint inhibitor, was approved by the FDA in 2020 for patients with advanced bladder cancer which has shrunk or stopped growing after receiving platinum-based chemotherapy.
Avelumab has been approved for the adjuvant treatment of bladder cancer that has not metastasized (locally advanced) or that has spread beyond the bladder (metastatic carcinoma).
Clinical Trial
Bladder cancer treatment depends on the type and stage of the disease. Research on new treatments and drugs is ongoing in addition to new combinations of existing treatments.
Drugs used in targeted therapy target specific cancer cells while causing little damage to normal cells. FDA approved erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial cancer in 2019.
A patient with an altered FGFR2 or FGFR3 gene may benefit from this medicine. It is estimated that FGFR gene mutations are responsible for 20% of bladder cancer cases.
Patients with advanced bladder cancer and mutations in the FGFR gene are undergoing a phase 3 trial that compares erdafitinib with standard chemotherapy and pembrolizumab.
The purpose of this study is to determine whether erdafitinib or an immune checkpoint inhibitor may be more beneficial in treating FGFR-mutant bladder cancer patients than chemotherapy.
In phase 3 trials, patients with muscle-invasive bladder cancer are receiving chemotherapy and radiation therapy with and without immune checkpoint inhibitor atezolizumab. Radiation therapy and chemotherapy combine to kill more cancer cells than chemotherapy alone. Patients with muscle-invasive bladder cancer may achieve better outcomes when atezolizumab (Tecentriq) is combined with radiation therapy and chemotherapy.
The monoclonal antibodies are proteins made in the laboratory and can bind to specific targets in the body, such as cancer cells. Monoclonal antibodies are chemically linked to drugs to form antibody-drug conjugates. It can kill cancer cells without harming normal cells.
Enfortumab vedotin-ejfv (Padcev) is also approved for treating advanced or metastatic bladder cancer. Positive results have been observed in patients who have previously been treated with chemotherapy and immune checkpoint inhibitors. A study is ongoing to determine whether this drug can be used together with immunotherapy and/or chemotherapy to treat bladder cancer early.
Competitive Landscape
The report gives an in-depth analysis of the top players involved in the global bladder cancer treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- AstraZeneca Plc.
- Bristol-Myers Squibb Co.
- Celgene Corporation
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Novartis International AG
- Sanofi S.A.
- Merck & Co. Inc.
- Genetech Inc.
- Johnson & Johnson Services, Inc
- Viventia Bio Inc.
- Spectrum Pharmaceuticals, Inc.
- Herantis Pharma Plc.
- Taris Biomedical LLC
- Prometic Life Sciences Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Method |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Bladder Cancer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Bladder Cancer Treatment Market
6.1 Global Bladder Cancer Treatment Market Overview
6.2 Global Bladder Cancer Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Bladder Cancer Treatment Market Historical Value (2016-2022)
6.2.1.2 Global Bladder Cancer Treatment Market Forecast Value (2023-2031)
6.2.2 Global Bladder Cancer Treatment Market by Type
6.2.2.1 Market Overview
6.2.2.1.1 Invasive Bladder Cancer
6.2.2.1.1.1 Non-Muscle-Invasive Bladder Cancer
6.2.2.1.1.2 Muscle-Invasive Bladder Cancer
6.2.2.1.2 Transitional Bladder Cancer
6.2.2.1.3 Squamous Cell Bladder Cancer
6.2.2.1.4 Others
6.2.3 Global Bladder Cancer Treatment Market by Diagnosis Method
6.2.3.1 Market Overview
6.2.3.1.1 Cystoscopy
6.2.3.1.2 Biopsy
6.2.3.1.3 Urine Cytology
6.2.3.1.4 Imaging Tests
6.2.4 Global Bladder Cancer Treatment Market by Treatment Method
6.2.4.1 Market Overview
6.2.4.1.1 Surgery
6.2.4.1.2 Intravesical Chemotherapy
6.2.4.1.3 Systemic Chemotherapy
6.2.4.1.4 Radiation Therapy
6.2.4.1.5 Immunotherapy
6.2.4.1.6 Targeted Therapy
6.2.5 Global Bladder Cancer Treatment Market by Treatment Channel
6.2.5.1 Market Overview
6.2.5.1.1 Public
6.2.5.1.2 Private
6.2.6 Global Bladder Cancer Treatment Market by Region
6.2.6.1 Market Overview
6.2.6.1.1 North America
6.2.6.1.2 Europe
6.2.6.1.3 Asia Pacific
6.2.6.1.4 Latin America
6.2.6.1.5 Middle East and Africa
6.2.6.2 North America
6.2.6.2.1 Historical Trend (2016-2022)
6.2.6.2.2 Forecast Trend (2023-2031)
6.2.6.2.3 Break Up by Country
6.2.6.2.3.1 United States of America
6.2.6.2.3.2 Canada
6.2.6.3 Europe
6.2.6.3.1 Historical Trend (2016-2022)
6.2.6.3.2 Forecast Trend (2023-2031)
6.2.6.3.3 Break Up by Country
6.2.6.3.3.1 United Kingdom
6.2.6.3.3.2 Germany
6.2.6.3.3.3 France
6.2.6.3.3.4 Italy
6.2.6.3.3.5 Others
6.2.6.4 Asia Pacific
6.2.6.4.1 Historical Trend (2016-2022)
6.2.6.4.2 Forecast Trend (2023-2031)
6.2.6.4.3 Break Up by Country
6.2.6.4.3.1 China
6.2.6.4.3.2 Japan
6.2.6.4.3.3 India
6.2.6.4.3.4 ASEAN
6.2.6.4.3.5 Australia
6.2.6.4.3.6 Others
6.2.6.5 Latin America
6.2.6.5.1 Historical Trend (2016-2022)
6.2.6.5.2 Forecast Trend (2023-2031)
6.2.6.5.3 Break Up by Country
6.2.6.5.3.1 Brazil
6.2.6.5.3.2 Argentina
6.2.6.5.3.3 Mexico
6.2.6.5.3.4 Others
6.2.6.6 Middle East and Africa
6.2.6.6.1 Historical Trend (2016-2022)
6.2.6.6.2 Forecast Trend (2023-2031)
6.2.6.6.3 Break Up by Country
6.2.6.6.3.1 Saudi Arabia
6.2.6.6.3.2 United Arab Emirates
6.2.6.6.3.3 Nigeria
6.2.6.6.3.4 South Africa
6.2.6.6.3.5 Others
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials Synopsis
7.2 Patent Landscape
7.2.1 Patent Overview
7.2.1.1 Patent Status and Expiry
7.2.1.2 Timelines from Drug Development to Commercial Launch
7.2.1.3 New Drug Application
7.2.1.3.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Regulatory Framework
7.4.1 Regulatory Overview
7.4.1.1 US FDA
7.4.1.2 EU EMA
7.4.1.3 INDIA CDSCO
7.4.1.4 JAPAN PMDA
7.4.1.5 Others
8 Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Bladder Cancer Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives and Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 AstraZeneca Plc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Bristol-Myers Squibb Co.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Celgene Corporation
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 GlaxoSmithKline Plc.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Eli Lilly and Company
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 F. Hoffmann-La Roche AG
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Novartis International AG
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Sanofi S.A.
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Merck & Co. Inc.
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Genetech Inc.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
10.12 Johnson & Johnson Services, Inc
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Viventia Bio Inc.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Spectrum Pharmaceuticals, Inc.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
10.15 Herantis Pharma Plc.
10.15.1 Company Overview
10.15.2 Product Portfolio
10.15.3 Demographic Reach and Achievements
10.15.4 Mergers and Acquisitions
10.15.5 Certifications
10.16 Taris Biomedical LLC
10.16.1 Company Overview
10.16.2 Product Portfolio
10.16.3 Demographic Reach and Achievements
10.16.4 Mergers and Acquisitions
10.16.5 Certifications
10.17 Prometic Life Sciences Inc.
10.17.1 Company Overview
10.17.2 Product Portfolio
10.17.3 Demographic Reach and Achievements
10.17.4 Mergers and Acquisitions
10.17.5 Certifications
11 Recommendations and Discussion
12 Global Bladder Cancer Treatment Drugs Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is likely to grow at a CAGR of 9.31% during the forecast period of 2023-2031.
The market attained a value of USD 4.03 billion in 2022.
The market is expected to reach a value of USD 8.98 billion by 2031.
The factors stimulating the development of the market are bladder infections, genetic alteration, smoking, and chemical exposure, and a rise in R&D expenditure in biopharmaceutical companies.
Lack of awareness and rising treatment cost are the suspected reasons for hindering the growth of this market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
The top companies involved are AstraZeneca Plc., Bristol-Myers Squibb Co., Celgene Corporation, Pfizer Inc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., Merck & Co. Inc., Genetech Inc., Johnson & Johnson Services, Inc, Viventia Bio Inc., Spectrum Pharmaceuticals, Inc., Herantis Pharma Plc., Prometic Life Sciences Inc., and Taris Biomedical LLC.
The detection of non-muscle invasive bladder cancer can be done through blood tests, urine cytology, cystoscopy, or computerised tomography.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER